Compare Fresenius Kabi Onco. with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs TORRENT PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. TORRENT PHARMA FRESENIUS KABI ONCO./
TORRENT PHARMA
 
P/E (TTM) x 22.1 38.5 57.4% View Chart
P/BV x 3.1 9.8 31.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 FRESENIUS KABI ONCO.   TORRENT PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
TORRENT PHARMA
Mar-19
FRESENIUS KABI ONCO./
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,964 9.0%   
Low Rs791,245 6.3%   
Sales per share (Unadj.) Rs37.7453.4 8.3%  
Earnings per share (Unadj.) Rs5.125.8 19.8%  
Cash flow per share (Unadj.) Rs6.762.3 10.8%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs42.5279.2 15.2%  
Shares outstanding (eoy) m158.23169.22 93.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.5 95.4%   
Avg P/E ratio x25.062.2 40.1%  
P/CF ratio (eoy) x18.925.8 73.5%  
Price / Book Value ratio x3.05.7 52.0%  
Dividend payout %065.9 0.0%   
Avg Mkt Cap Rs m20,135271,513 7.4%   
No. of employees `0001.213.6 8.5%   
Total wages/salary Rs m70314,038 5.0%   
Avg. sales/employee Rs Th5,176.25,642.6 91.7%   
Avg. wages/employee Rs Th610.41,032.4 59.1%   
Avg. net profit/employee Rs Th699.6320.9 218.0%   
INCOME DATA
Net Sales Rs m5,96376,728 7.8%  
Other income Rs m18571 3.2%   
Total revenues Rs m5,98177,299 7.7%   
Gross profit Rs m1,43019,831 7.2%  
Depreciation Rs m2586,177 4.2%   
Interest Rs m-265,038 -0.5%   
Profit before tax Rs m1,2169,187 13.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68-3,570 1.9%   
Tax Rs m3421,254 27.3%   
Profit after tax Rs m8064,363 18.5%  
Gross profit margin %24.025.8 92.8%  
Effective tax rate %28.113.6 206.2%   
Net profit margin %13.55.7 237.7%  
BALANCE SHEET DATA
Current assets Rs m5,10250,375 10.1%   
Current liabilities Rs m2,38551,653 4.6%   
Net working cap to sales %45.6-1.7 -2,735.2%  
Current ratio x2.11.0 219.3%  
Inventory Days Days15092 163.0%  
Debtors Days Days11368 165.9%  
Net fixed assets Rs m5,14883,648 6.2%   
Share capital Rs m158846 18.7%   
"Free" reserves Rs m6,55646,397 14.1%   
Net worth Rs m6,73247,244 14.2%   
Long term debt Rs m95239,129 2.4%   
Total assets Rs m10,388141,209 7.4%  
Interest coverage x-45.82.8 -1,621.2%   
Debt to equity ratio x0.10.8 17.1%  
Sales to assets ratio x0.60.5 105.6%   
Return on assets %7.56.7 112.8%  
Return on equity %12.09.2 129.6%  
Return on capital %14.612.3 118.4%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29822,103 24.0%   
Fx outflow Rs m1,7725,522 32.1%   
Net fx Rs m3,52516,581 21.3%   
CASH FLOW
From Operations Rs m1,27417,981 7.1%  
From Investments Rs m-1,204-2,413 49.9%  
From Financial Activity Rs m-196-13,145 1.5%  
Net Cashflow Rs m-1262,380 -5.3%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 7.0 4.3%  
FIIs % 9.6 12.6 76.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.8 103.4%  
Shareholders   42,599 26,511 160.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   NATCO PHARMA  STRIDES PHARMA SCIENCE  FDC  ABBOTT INDIA  DISHMAN PHARMA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - PIRAMAL ENTERPRISES COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS